Emergent Biodefense Drug Patent Portfolio
Emergent Biodefense owns 1 orange book drug protected by 5 US patents Given below is the list of Emergent Biodefense's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10112909 | Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof | 10 Oct, 2034 | Active |
| US10487061 | Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof | 10 Oct, 2034 | Active |
| US8962829 | Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof | 10 Oct, 2034 | Active |
| US9371344 | Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof | 10 Oct, 2034 | Active |
| US9303051 | Phosphonate ester derivatives and methods of synthesis thereof | 31 Aug, 2031 | Active |
Latest Legal Activities on Emergent Biodefense's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Emergent Biodefense.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| transaction for FDA Determination of Regulatory Review Period | 29 Feb, 2024 | US9303051 |
| transaction for FDA Determination of Regulatory Review Period | 07 Feb, 2024 | US9303051 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 06 Dec, 2023 | US9371344 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 20 Sep, 2023 | US9303051 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 10 May, 2023 | US10487061 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 14 Feb, 2023 | US9371344 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 14 Feb, 2023 | US8962829 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 14 Feb, 2023 | US9303051 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 14 Feb, 2023 | US10112909 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 08 Feb, 2023 | US10487061 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 10 Jan, 2023 | US10487061 |
|
Email Notification
Critical
| 10 Jan, 2023 | US10487061 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 10 Jan, 2023 | US10112909 |
|
Email Notification
Critical
| 10 Jan, 2023 | US10112909 |
|
Email Notification
Critical
| 09 Jan, 2023 | US9303051 |
Emergent Biodefense's Family Patents
Emergent Biodefense drugs have patent protection in a total of 15 countries. It's US patent count contributes only to 26.9% of its total global patent coverage. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click
below to unlock the full patent family tree.
Emergent Biodefense Drug List
Given below is the complete list of Emergent Biodefense's drugs and the patents protecting them.
1. Tembexa
Tembexa is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10112909 | Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof |
10 Oct, 2034
(9 years from now)
| Active |
| US10487061 | Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof |
10 Oct, 2034
(9 years from now)
| Active |
| US8962829 | Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof |
10 Oct, 2034
(9 years from now)
| Active |
| US9371344 | Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof |
10 Oct, 2034
(9 years from now)
| Active |
| US9303051 | Phosphonate ester derivatives and methods of synthesis thereof |
31 Aug, 2031
(6 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tembexa's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List